Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeDropped

Termination of the Sales Agreement With Teijin Pharma Limited for an Improved Fenofibrate Formulation

First written in FY2022-Q3. 1 of 1 entries say "Dropped", first in FY2022-Q3. Latest entry: FY2022-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Termination of Sales Rights Agreement for Improved Fenofibrate FormulationA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2022-Q3DroppedAnnual report

    「Sales agreement Contracting company: Asuka Pharmaceutical Co., Ltd. Counterparty: Teijin Pharma Limited Country: Japan Product: Improved fenofibrate formulation Terms: Licensed sales rights Term: 7 years after the launch in September 2010, with automatic annual renewal thereafter」

    帝人ファーマ株式会社から許諾を受けていたフェノフィブラート改良製剤の販売権契約を、終了した重要な契約として記載している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.